286 related articles for article (PubMed ID: 2974279)
21. Kinetics of the reactions between streptokinase, plasmin and alpha 2-antiplasmin.
Cederholm-Williams SA; De Cock F; Lijnen HR; Collen D
Eur J Biochem; 1979 Oct; 100(1):125-32. PubMed ID: 158524
[TBL] [Abstract][Full Text] [Related]
22. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate.
Teger-Nilsson AC; Friberger P; Gyzander E
Scand J Clin Lab Invest; 1977 Sep; 37(5):403-9. PubMed ID: 73215
[TBL] [Abstract][Full Text] [Related]
23. Kinetic study of the effect of heparin on the amidase activity of trypsin, plasmin and urokinase.
Yomtova VM; Stambolieva NA; Blagoev BM
Thromb Haemost; 1983 Jun; 49(3):199-203. PubMed ID: 6224310
[TBL] [Abstract][Full Text] [Related]
24. [Study of structural features of macroglobulins complexed with plasmin].
Zhabin SG; Zorin NA; Gorin VS; Lykova OF
Vopr Med Khim; 1993; 39(4):53-6. PubMed ID: 8379118
[TBL] [Abstract][Full Text] [Related]
25. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
[TBL] [Abstract][Full Text] [Related]
26. Soluble fibrin preparations inhibit the reaction of plasmin with alpha 2-macroglobulin. Comparison with alpha 2-antiplasmin and leupeptin.
Anonick PK; Gonias SL
Biochem J; 1991 Apr; 275 ( Pt 1)(Pt 1):53-9. PubMed ID: 1708234
[TBL] [Abstract][Full Text] [Related]
27. Identification of amino acids in antiplasmin involved in its noncovalent 'lysine-binding-site'-dependent interaction with plasmin.
Wang H; Yu A; Wiman B; Pap S
Eur J Biochem; 2003 May; 270(9):2023-9. PubMed ID: 12709062
[TBL] [Abstract][Full Text] [Related]
28. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin.
Schneider M; Brufatto N; Neill E; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13340-5. PubMed ID: 14715654
[TBL] [Abstract][Full Text] [Related]
29. Plasmin's peptide-binding specificity: characterization of ligand sites in alpha 2-antiplasmin.
Hortin GL; Trimpe BL; Fok KF
Thromb Res; 1989 Jun; 54(6):621-32. PubMed ID: 2551057
[TBL] [Abstract][Full Text] [Related]
30. Interaction of SK-human plasmin, SK-dog plasmin complexes with alpha 2-antiplasmin and alpha 2-macroglobulin.
Reddy KN; Cercek B; Lew AS; Ganz W
Thromb Res; 1986 Mar; 41(5):671-80. PubMed ID: 2421434
[TBL] [Abstract][Full Text] [Related]
31. Alpha 2-antiplasmin's carboxy-terminal lysine residue is a major site of interaction with plasmin.
Hortin GL; Gibson BL; Fok KF
Biochem Biophys Res Commun; 1988 Sep; 155(2):591-6. PubMed ID: 2458720
[TBL] [Abstract][Full Text] [Related]
32. Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and alpha(2)-antiplasmin.
Ries M; Easton RL; Longstaff C; Zenker M; Morris HR; Dell A; Gaffney PJ
Thromb Res; 2002 Feb; 105(3):247-56. PubMed ID: 11927131
[TBL] [Abstract][Full Text] [Related]
33. Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma.
Müllertz S; Thorsen S; Sottrup-Jensen L
Biochem J; 1984 Oct; 223(1):169-77. PubMed ID: 6208893
[TBL] [Abstract][Full Text] [Related]
34. The kinetics of plasmin inhibition by aprotinin in vivo.
Kang HM; Kalnoski MH; Frederick M; Chandler WL
Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
[TBL] [Abstract][Full Text] [Related]
35. Changes in antiplasmin and plasmin activities during extreme hemodilution and open heart surgery in dogs.
Aasen AO; Gallimore MJ; Lilleaasen P; Lyngaas K; Larsbraaten M; Amundsen E
Eur Surg Res; 1979; 11(3):145-53. PubMed ID: 159822
[TBL] [Abstract][Full Text] [Related]
36. The suitability of various plasmin preparations for the functional assay of alpha 2-antiplasmin in plasma.
Kluft C; Traas DW; Jie AF; Hoegee-de Nobel E
Thromb Haemost; 1982 Dec; 48(3):320-4. PubMed ID: 6219471
[TBL] [Abstract][Full Text] [Related]
37. Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells.
Koyama T; Koike Y; Toyota S; Miyagi F; Suzuki N; Aoki N
Biochem Biophys Res Commun; 1994 Apr; 200(1):417-22. PubMed ID: 8166714
[TBL] [Abstract][Full Text] [Related]
38. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.
Carpenter SL; Mathew P
Haemophilia; 2008 Nov; 14(6):1250-4. PubMed ID: 19141165
[TBL] [Abstract][Full Text] [Related]
39. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
Sakata Y; Aoki N
J Clin Invest; 1980 Feb; 65(2):290-7. PubMed ID: 6444305
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of plasmin by beta-lactoglobulin using casein and a synthetic substrate.
Bastian ED; Hansen KG; Brown RJ
J Dairy Sci; 1993 Nov; 76(11):3354-61. PubMed ID: 8270680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
